|
|
||||||||


Departments of
* Medical Oncology and
Immunology, Cancer Research Campaign, Paterson Institute of Cancer Research, Christie Hospital National Health Service Trust, Manchester, United Kingdom
The Ig Id of a B cell lymphoma is a tumor-specific Ag, although as
a self-Ag it is likely to be a weak immunogen. Provision of a foreign
gene may enhance the immunogenicity of the idiotype. Viral vectors
allow highly efficient transfer of genetic material and are themselves
innately immunogenic. We have investigated the ability of recombinant
adenoviral vectors, encoding the idiotypic gene with or without fusion
to the human Fc region, to produce anti-idiotypic Ab- and T
cell-mediated responses in a syngeneic BALB/c A20 murine lymphoma
model. The idiotypic VH and VL sequences were
assembled as a single chain variable fragment (scFv) and adenoviral
vectors encoding the A20 scFv (Ad.A20) and A20 scFv linked to
the Fc fragment of human IgG1 (Ad.A20hFc) were constructed. A
single immunization of BALB/c mice with Ad.A20hFc but not Ad.A20
induced a specific anti-idiotypic Ab response. T cell lines
generated from mice vaccinated with either vector displayed specific
cytotoxicity, proliferation, and IFN-
release against a syngeneic
dendritic cell line transduced using a retroviral vector to express the
A20 scFv idiotype (XS52.A1.A20). Importantly, both T cell lines lysed
the A20 lymphoma cells. An immunodominant H-2Kd-restricted
CD8+ T cell peptide, DYWGQGTEL (A20[106114]), was
identified as a naturally occurring A20 scFv epitope. A single
immunization with Ad.A20hFc but not Ad.A20 provided protection in
>40% of animals challenged with a lethal dose of the A20 tumor line
and was more effective, in this model, than a previously optimized
plasmid vaccine.
This article has been cited by other articles:
![]() |
D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas J. Immunol., September 15, 2008; 181(6): 4131 - 4140. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Fredriksen and B. Bogen Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences Blood, September 15, 2007; 110(6): 1797 - 1805. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Schjetne, A. B. Fredriksen, and B. Bogen Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors J. Immunol., April 1, 2007; 178(7): 4169 - 4176. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schiavo, D. Baatar, P. Olkhanud, F. E. Indig, N. Restifo, D. Taub, and A. Biragyn Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses Blood, June 15, 2006; 107(12): 4597 - 4605. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. U. Lundin, P. O. Hofgaard, H. Omholt, L. A. Munthe, A. Corthay, and B. Bogen Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies Blood, July 15, 2003; 102(2): 605 - 612. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |